• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同粪便免疫化学检测联合用于结直肠癌筛查:诊断性能有提高吗?

Combination of Different Fecal Immunochemical Tests in Colorectal Cancer Screening: Any Gain in Diagnostic Performance?

作者信息

Gies Anton, Cuk Katarina, Schrotz-King Petra, Brenner Hermann

机构信息

Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.

Medical Faculty Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.

出版信息

Cancers (Basel). 2019 Jan 20;11(1):120. doi: 10.3390/cancers11010120.

DOI:10.3390/cancers11010120
PMID:30669538
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6356298/
Abstract

A variety of fecal immunochemical tests (FITs) are used for colorectal cancer screening. FIT performance could be improved further. It is unclear, whether the combination of different FITs with different analytical characteristics (such as, different antibodies for the detection of fecal hemoglobin) can yield a better diagnostic performance. Fecal samples were obtained from 2042 participants of screening colonoscopy. All participants with advanced neoplasm (AN, colorectal cancer ( = 16) or advanced adenoma ( = 200)) and 300 randomly selected participants without AN were included. Nine quantitative FITs were evaluated simultaneously. Sensitivity and specificity was calculated for single tests ( = 9) and for their pairwise test combinations ( = 36) (requiring either both FITs (P++) or at least one FIT (P+) to be positive for defining a positive test result). Mean age of the participants ( = 516) was 63 (range: 50⁻79) years and 56% were men. At cutoffs yielding a specificity of 96.7% for single FITs, the median gain in specificity by P++ combination was +1.0%, whereas the median loss in sensitivity for AN was -4.2%. For P+ combination the median gain in sensitivity for AN was +2.8%, at a prize of median loss of -1.0% of specificity. Combinations of different FITs do not yield any relevant gain in diagnostic performance.

摘要

多种粪便免疫化学检测(FIT)用于结直肠癌筛查。FIT的性能可进一步提高。目前尚不清楚,具有不同分析特征的不同FIT(例如,用于检测粪便血红蛋白的不同抗体)组合是否能产生更好的诊断性能。从2042名接受结肠镜筛查的参与者中获取粪便样本。纳入所有患有晚期肿瘤(AN,结直肠癌(n = 16)或晚期腺瘤(n = 200))的参与者以及300名随机选择的无AN的参与者。同时评估了九种定量FIT。计算了单项检测(n = 9)及其两两检测组合(n = 36)的敏感性和特异性(定义阳性检测结果要求两个FIT(P++)或至少一个FIT(P+)为阳性)。参与者(n = 516)的平均年龄为63岁(范围:50 - 79岁),56%为男性。对于单项FIT,在特异性为96.7%的临界值下,P++组合的特异性中位数增加为+1.0%,而AN的敏感性中位数损失为 - 4.2%。对于P+组合,AN的敏感性中位数增加为+2.8%,代价是特异性中位数损失 - 1.0%。不同FIT的组合在诊断性能上没有产生任何相关的提升。

相似文献

1
Combination of Different Fecal Immunochemical Tests in Colorectal Cancer Screening: Any Gain in Diagnostic Performance?不同粪便免疫化学检测联合用于结直肠癌筛查:诊断性能有提高吗?
Cancers (Basel). 2019 Jan 20;11(1):120. doi: 10.3390/cancers11010120.
2
Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening.9 种用于结直肠癌筛查的定量粪便免疫化学检测方法的诊断性能直接比较。
Gastroenterology. 2018 Jan;154(1):93-104. doi: 10.1053/j.gastro.2017.09.018. Epub 2017 Sep 25.
3
4
Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.两种定量粪便免疫化学检测在有组织结直肠癌筛查项目中检测高级别腺瘤的准确性相当。
Gastroenterology. 2018 Nov;155(5):1392-1399.e5. doi: 10.1053/j.gastro.2018.07.021. Epub 2018 Jul 25.
5
Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.结直肠癌筛查项目中粪便血红蛋白浓度对晚期结直肠肿瘤的风险分层。
Gastroenterology. 2014 Sep;147(3):628-636.e1. doi: 10.1053/j.gastro.2014.06.008. Epub 2014 Jun 14.
6
Optimizing sampling device for the fecal immunochemical test increases colonoscopy yields in colorectal cancer screening.优化粪便免疫化学检测的采样装置可提高结直肠癌筛查中结肠镜检查的阳性率。
Eur J Cancer Prev. 2016 Mar;25(2):115-22. doi: 10.1097/CEJ.0000000000000154.
7
Diagnostic Accuracy of a Qualitative Fecal Immunochemical Test Varies With Location of Neoplasia But Not Number of Specimens.定性粪便免疫化学检测的诊断准确性随肿瘤位置而异,但与标本数量无关。
Clin Gastroenterol Hepatol. 2015 Aug;13(8):1472-9. doi: 10.1016/j.cgh.2015.02.021. Epub 2015 Feb 24.
8
9
Fecal immunochemical test for hemoglobin in combination with fecal transferrin in colorectal cancer screening.粪便血红蛋白免疫化学检测联合粪便转铁蛋白用于结直肠癌筛查
United European Gastroenterol J. 2018 Oct;6(8):1223-1231. doi: 10.1177/2050640618784053. Epub 2018 Jun 12.
10
Fecal Immunochemical Tests Detect Screening Participants with Multiple Advanced Adenomas Better than T1 Colorectal Cancers.粪便免疫化学检测在筛查出患有多个进展性腺瘤的参与者方面,比筛查出T1期结直肠癌更为有效。
Cancers (Basel). 2021 Feb 5;13(4):644. doi: 10.3390/cancers13040644.

引用本文的文献

1
Consistent Major Differences in Sex- and Age-Specific Diagnostic Performance among Nine Faecal Immunochemical Tests Used for Colorectal Cancer Screening.用于结直肠癌筛查的九种粪便免疫化学检测在性别和年龄特异性诊断性能上存在一致的主要差异。
Cancers (Basel). 2021 Jul 16;13(14):3574. doi: 10.3390/cancers13143574.
2
Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort.粪便 B 细胞激活因子在腹部不适患者中的诊断价值。
Clin Exp Immunol. 2019 Nov;198(2):131-140. doi: 10.1111/cei.13350. Epub 2019 Aug 5.

本文引用的文献

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
Direct comparison of ten quantitative fecal immunochemical tests for hemoglobin stability in colorectal cancer screening.直接比较十种用于结直肠癌筛查的粪便免疫化学试验定量检测血红蛋白稳定性的比较。
Clin Transl Gastroenterol. 2018 Jul 6;9(7):168. doi: 10.1038/s41424-018-0035-2.
3
Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.
美国癌症协会 2018 年普通风险成年人结直肠癌筛查指南更新
CA Cancer J Clin. 2018 Jul;68(4):250-281. doi: 10.3322/caac.21457. Epub 2018 May 30.
4
Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study.定量粪便免疫化学检测用于检测结直肠高级别瘤变的性能:一项前瞻性队列研究。
BMC Cancer. 2018 May 2;18(1):509. doi: 10.1186/s12885-018-4402-x.
5
Variation of diagnostic performance of fecal immunochemical testing for hemoglobin by sex and age: results from a large screening cohort.粪便免疫化学检测血红蛋白的诊断性能按性别和年龄的变化:来自一个大型筛查队列的结果。
Clin Epidemiol. 2018 Apr 5;10:381-389. doi: 10.2147/CLEP.S155548. eCollection 2018.
6
Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations.系统评价结直肠癌筛查指南在一般风险成年人中的应用:总结当前全球建议。
World J Gastroenterol. 2018 Jan 7;24(1):124-138. doi: 10.3748/wjg.v24.i1.124.
7
Quantitative fecal immunochemical tests for colorectal cancer screening.定量粪便免疫化学试验用于结直肠癌筛查。
Int J Cancer. 2018 Jul 15;143(2):234-244. doi: 10.1002/ijc.31233. Epub 2018 Jan 12.
8
Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening.9 种用于结直肠癌筛查的定量粪便免疫化学检测方法的诊断性能直接比较。
Gastroenterology. 2018 Jan;154(1):93-104. doi: 10.1053/j.gastro.2017.09.018. Epub 2017 Sep 25.
9
Which Fecal Immunochemical Test Should I Choose?我应该选择哪种粪便免疫化学检测?
J Prim Care Community Health. 2017 Oct;8(4):264-277. doi: 10.1177/2150131917705206. Epub 2017 Apr 27.
10
Fresh vs Frozen Samples and Ambient Temperature Have Little Effect on Detection of Colorectal Cancer or Adenomas by a Fecal Immunochemical Test in a Colorectal Cancer Screening Cohort in Germany.新鲜样本与冷冻样本及室温对粪便免疫化学试验检测德国结直肠癌筛查队列中结直肠癌或腺瘤的影响较小。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1547-1556.e5. doi: 10.1016/j.cgh.2016.10.018. Epub 2016 Oct 26.